There is one clinical trial.
This is a research study to see how safe and effective decidual stromal cells are in treating
patients with respiratory failure (breathing problem where not enough oxygen is passed from
the lungs into the blood) caused by COVID-19.
Primary Outcomes
Measure: Number of ventilator free days following infusion of decidual stromal cells Time: 28 days
Secondary Outcomes
Measure: Mortality rate from COVID-19 Time: 28 days
Measure: Mortality rate from COVID-19 Time: 60 days
Measure: Mortality rate from COVID-19 Time: 180 days
Measure: All-cause morality rate Time: 28 days
Measure: All-cause morality rate Time: 60 days
Measure: All-cause morality rate Time: 180 days
Measure: Average number of days in ICU Time: 180 days
Measure: Average number of days of hospital admittance Time: 180 days
Measure: Average days not requiring vasopressors Time: 180 days
Measure: Overall survival rate Time: 180 days
Measure: Average viral clearance Time: 180 days
Measure: Average number of days of supplemental oxygenation Time: 180 days
Measure: Average number of day without supplemental oxygen Time: 180 days
Measure: Mean PaO2/FiO2 as compared to patient baseline Time: 180 days